Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for higher-risk myelodysplastic syndromes (HR-MDS) after obtaining disappointing efficacy data from a Phase III trial. Although the company has not yet released the results, it has confirmed that the study’s primary endpoints included complete response (CR) and overall survival (OS), with secondary endpoints focusing on duration of response, transfusion independence, progression-free survival (PFS), and time to transformation to acute myeloid leukemia (AML).
Consistent Safety Profile, Shift in Development Focus
The firm noted that the safety profile of magrolimab was consistent with previous observations. Despite the setback in HR-MDS, the drug is still on track to enter development for several hematologic cancers and solid tumor malignancies. Additionally, ongoing studies are continuing in AML with TP53 mutations and in first-line, unfit AML patients.-Fineline Info & Tech
